Earlier in January 2011, Plexxikon has started patient recruitment in first of two Phase 1 clinical trials with PLX5622.
The initial Phase 1 trial is a single-ascending dose (SAD) study in up to 48 healthy volunteers.
The second trial is a multiple-ascending dose (MAD) study in approximately 32 RA patients that will begin once the first SAD healthy volunteer cohort has been cleared for safety, with continued enrollment in a staggered fashion following each SAD dose level.
Both studies are being managed by Clinipace Worldwide.
Plexxikon Business Development director said they chose Clinipace Worldwide to manage these important clinical trials for both PLX5622 and PLX3397 based on Clinipace’s commitment to customer service.